natgillin/translations-raw huggingface dataset:
For mild and moderate renal impairment (creatinine clearance ≥ 30 and &lt; 80 mL/min): the dose recommendations are the same as for adults without renal impairment.
Kod blagog i umjerenog oštećenja funkcije bubrega (klirens kreatinina ≥ 30 i &lt; 80 ml/min) preporučuju se iste doze kao i za odrasle bolesnike koji nemaju oštećenje funkcije bubrega.
For monitoring, the attainment of a normal peak bone mass defined as a T score &gt; - 1 (i.e. standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account gender and ethnicity) is one of the therapeutic objectives during the transition period.
Kod praćenja, postizanje normalne vršne koštane mase definirane kao T rezultat &gt; -1 (tj., standardiziran prema prosječnoj vršnoj koštanoj masi u odraslih mjerenoj dvostrukom apsorpciometrijom X-zraka uzimajući u obzir spol i etnicitet) jedan je od terapijskih ciljeva tijekom prijelaznog razdoblja.
For monitoring, the attainment of a normal peak bone mass defined as a T score &gt; - 1 (i.e. standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account gender and ethnicity) is one of the therapeutic objectives during the transition period.
Kod praćenja, postizanje normalne vršne koštane mase definirane kao T rezultat &gt; -1 (tj., standardiziran prema prosječnoj vršnoj koštanoj masi u odraslih mjerenoj dvostrukom apsorpciometrijom X-zraka uzimajućiu obzir spol i etnicitet) jedan je od terapijskih ciljeva tijekom prijelaznog razdoblja.
For monitoring, the attainment of a normal peak bone mass defined as a T score &gt; -1 (i.e. standardized to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period.
U svrhu praćenja, postizanje normalne vršne koštane mase definirane kao T-skor &gt; -1 (tj. standardiziran prema prosječnoj vršnoj koštanoj masi u odraslih mjerenoj dvoenergetskom apsorpciometrijom X-zraka, uzimajući u obzir spol i etničku pripadnost) jedan je od terapijskih ciljeva u prijelaznom razdoblju.
For paediatric patients who weigh &lt; 47 kg or cannot swallow capsules, see ribavirin oral solution SPC.)
Za pedijatrijske bolesnike tjelesne težine &lt; 47 kg ili bolesnike koji ne mogu progutati kapsule, vidjeti Sažetak opisa svojstava lijeka ribavirin oralna otopina).
For patients &lt; 3 years of age, trough concentrations should be monitored at least 1 week after start of treatment or after any change in dose or pharmaceutical form (see section 5.2).
Za bolesnike mlađe od 3 godine, najniže koncentracije se moraju odrediti najranije 1 tjedan nakon početka liječenja ili nakon bilo koje promjene u dozi ili farmaceutskom obliku (vidjeti dio 5.2).
For patients &lt; 75 kg and 75 kg, 1000 mg daily and 1200 mg daily of ribavirin, respectively, and regardless of genotype, should be administered.
U bolesnika čija je težina &lt; 75 kg potrebno je primijeniti dnevnu dozu od 1000 mg ribavirina, a u onih čija je težina 75 kg potrebno je primijeniti dnevnu dozu od 1200 mg ribavirina bez obzira na genotip virusa.
For patients &gt; 75 years of age, the starting dose of dexamethasone is 20 mg once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
U bolesnika u dobi od &gt; 75 godina, početna doza deksametazona je 20 mg jedanput na dan 1., 8., 15. i 22. dana svakog 28-dnevnog ciklusa liječenja.
For patients &gt; 75 years of age, the thalidomide recommended starting dose is 100 mg per day.
Za bolesnike starije od 75 godina, preporučena početna doza talidomida je 100 mg na dan.
For patients demonstrating a subsequent increase in QT-interval to &gt; 480 msec or increase by &gt; 20 msec after commencing concomitant therapy, the physician should use best clinical judgment to discontinue either ritonavir-boosted Invirase or the concomitant therapy or both.
Bolesnicima u kojih se utvrdi naknadno produljenje QT-intervala na &gt; 480 ms ili produljenje nakon započinjanja istodobnog liječenja za &gt; 20 ms, liječnik mora na temelju najbolje kliničke prosudbe prekinuti ili primjenu lijeka Invirase pojačanog ritonavirom, ili istodobne terapije ili oboje.
For patients in whom the dose was increased to &gt; 10 mg/kg, dose reduction to 10 mg/kg or less is recommended when LIC is &lt; 7 mg Fe/g dw or serum ferritin is ≤2,000 µg/l.
U bolesnika u kojih je doza povećana na &gt; 10 mg/kg, preporučuje se smanjenje doze na 10 mg/kg ili manje kad je LIC &lt; 7 mg Fe/g težine suhog tkiva jetre ili je serumski feritin ≤2000 µg/l.
For patients in whom the dose was increased to &gt; 7 mg/kg, dose reduction to 7 mg/kg or less is recommended when LIC is &lt; 7 mg Fe/g dw or serum ferritin is ≤2,000 µg/l.
U bolesnika u kojih je doza povećana na &gt; 7 mg/kg, preporučuje se smanjenje doze na 7 mg/kg ili manje kad je LIC &lt; 7 mg Fe/g težine suhog tkiva jetre ili je serumski feritin ≤2000 µg/l.
For patients infected with HCV genotype 1 &lt; 75 kg and 75 kg, 1000 mg daily and 1200 mg daily of ribavirin, respectively, should be administered.
U bolesnika zaraženih HCV-om genotipa 1 tjelesne mase &lt; 75 kg potrebno je primijeniti dnevnu dozu od 1000 mg ribavirina, a u onih čija je težina 75 kg potrebno je primijeniti dnevnu dozu od 1200 mg ribavirina.
For patients receiving a 800 mg ( &lt; 65 kg) - 1,000 mg (65-80 kg) - 1,200 mg (81-105 kg) or 1,400 mg ( &gt; 105 kg) dose, 1st dose reduction of Ribavirin Teva is by 200 mg/day (except in patients receiving the 1,400 mg, dose reduction should be by 400 mg/day).
U bolesnika koji primaju dozu od 800 mg ( &lt; 65 kg), 1000 mg (65–80 kg), 1200 mg (81–105 kg) ili 1400 mg ( &gt; 105 kg), prvo smanjenje doze lijeka Ribavirin Teva je za 200 mg/dan (osim u bolesnika koji primaju 1400 mg, u kojih dozu treba smanjiti za 400 mg/dan).
For patients treated with filgrastim diluted to concentrations &lt; 1.5 MU/ml (15 μg/ml), human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.
Za bolesnike liječene filgrastimom razrijeđenim do koncentracije &lt; 1,5 MU/ml (15 μg/ml), ljudski serumski albumin (HSA) treba se dodati do konačne koncentracije od 2 mg/ml.
For patients treated with filgrastim diluted to concentrations &lt; 1.5 MU/ml (15 μg/ml), human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.
Za bolesnike liječene filgrastimom razrijeđenim do koncentracije &lt; 1,5 MU/ml (15 μg/ml), treba dodati ljudski serumski albumin (HSA) do konačne koncentracije od 2 mg/ml.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolesnicima koji početnu dozu docetaksela od 75 mg/m2 primaju u kombinaciji s cisplatinom i u kojih je najniži broj trombocita tijekom prethodnog ciklusa liječenja iznosio &lt; 25.000 stanica/mm3, u bolesnika koji su imali febrilnu neutropeniju ili u bolesnika s ozbiljnim nehematološkim toksičnim učincima doza docetaksela u sljedećim ciklusima mora se smanjiti na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolesnicima koji početnu dozu docetaksela od 75 mg/m2 primaju u kombinaciji s cisplatinom i u kojih je najniži broj trombocita tijekom prethodnog ciklusa liječenja iznosio &lt; 25.000 stanica/mm3, u bolesnika koji su imali febrilnu neutropeniju ili u bolesnika s ozbiljnim nehematološkim toksičnim učincima, doza docetaksela u sljedećim ciklusima mora se smanjiti na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Bolesnicima koji početnu dozu docetaksela od 75 mg/m2 primaju u kombinaciji s cisplatinom i u kojih je najniži broj trombocita tijekom prethodnog ciklusa liječenja iznosio &lt; 25 000 stanica/mm3, u bolesnika koji su imali febrilnu neutropeniju ili u bolesnika s ozbiljnim nehematološkim toksičnim učincima, doza docetaksela u sljedećim ciklusima mora se smanjiti na 65 mg/m2.
For patients who are dosed initially at docetaxel 75 mg/m² in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is &lt; 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m².
Bolesnicima koji početnu dozu docetaksela od 75 mg/m2 primaju u kombinaciji s cisplatinom i u kojih je najniži broj trombocita tijekom prethodnog ciklusa liječenja iznosio &lt; 25.000 stanica/mm3, u bolesnika koji su imali febrilnu neutropeniju ili u bolesnika s ozbiljnim nehematološkim toksičnim učincima, doza docetaksela u sljedećim ciklusima mora se smanjiti na 65 mg/m2.
For patients with a baseline eGFR 30 mL/min/1.73 m2 to &lt; 60 mL/min/1.73 m2, the incidences were 4.8% on canagliflozin 100 mg and 8.1% on canagliflozin 300 mg compared to 2.6% in the control group.
Za bolesnike s početnom vrijednosti eGFR 30 mL/min/1,73 m2 do &lt; 60 mL/min/1,73 m2, incidencije su bile 4,8% uz kanagliflozin od 100 mg i 8,1% uz kanagliflozin od 300 mg u usporedbi s 2,6% u kontrolnoj skupini.
For patients with a baseline QT interval &lt; 450 msec, an on-treatment ECG should be performed.
U bolesnika s početnim QT-intervalom &lt; 450 ms, treba napraviti EKG tijekom liječenja.
For patients with a body weight &gt; 100 kg the initial dose is 90 mg administered subcutaneously, followed by a 90 mg dose 4 weeks later, and then every 12 weeks thereafter.
Bolesnicima tjelesne težine &gt; 100 kg supkutano se primjenjuje inicijalna doza od 90 mg, nakon čega slijedi nova doza od 90 mg 4 tjedna kasnije, a nakon toga svakih 12 tjedana.
For patients with a QT interval &lt; 450 msec, an on treatment ECG is recommended.
U bolesnika s QT-intervalom &lt; 450 ms preporučuje se napraviti EKG tijekom liječenja.
For patients with abnormal baseline creatinine ( &gt; 1.4 mg/dl or &gt; 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l.
povišenje vrijednosti kreatinina za 1,0 mg/dl ili 88 μmol/l u bolesnika s poremećenom početnom vrijednošću kreatinina ( &gt; 1,4 mg/dl ili &gt; 124 μmol/l).
For patients with abnormal baseline creatinine ( &gt; 1.4 mg/dl or &gt; 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l.
povišenje vrijednosti kreatinina za 1,0 mg/dl ili 88 μmol/l, u bolesnika s poremećenom početnom vrijednošću kreatinina ( &gt; 1,4 mg/dl ili &gt; 124 μmol/l).
For patients with an eGFR 60 mL/min/1.73 m2 to &lt; 90 mL/min/1.73 m2 or CrCl 60 mL/min to
U bolesnika s eGFR 60 mL/min/1,73 m2 do &lt; 90 mL/min/1,73 m2 ili s CrCl 60 mL/min do
For patients with AST or ALT elevations &gt; 8 x ULN or bilirubin &gt; 5 x ULN that are suspected to be related to ipilimumab, treatment must be permanently discontinued (see section 4.2), and systemic high-dose intravenous corticosteroid therapy (e.g. methylprednisolone 2 mg/kg daily or equivalent) should be initiated immediately.
U bolesnika s vrijednostima AST ili ALT povišenima &gt; 8 x GGN ili bilirubinom &gt; 5 x GGN za koje se vjeruje da su povezane s ipilimumabom, liječenje se mora trajno prekinuti (vidjeti dio 4.2) te je potrebno odmah uvesti intravensku sistemsku terapiju visokim dozama kortikosteroida (npr. metilprednizolon u dozi od 2 mg/kg na dan ili ekvivalentna terapija).
For patients with body weight &lt; 50 kg, the recommended dose is 5 mg.
Za bolesnike tjelesne težine &lt; 50 kg preporučena doza je 5 mg.
For patients with body weight &gt; 100 kg, the recommended dose is 10 mg.
Za bolesnike tjelesne težine &gt; 100 kg preporučena doza je 10 mg.
For patients with CrCl &lt; 60 mL/min, alternative antibacterials should be considered.
U pacijenata s CrCl &lt; 60 ml/min treba razmotriti alternativne antibakterijske lijekove.
For patients with creatinine clearance &lt; 30 mL/minute, additional considerations are necessary because elimination of enoxaparin is more prolonged.
Za bolesnike s klirensom kreatinina &lt; 30 ml/minuti potreban je dodatni oprez jer je kod njih vrijeme eliminacije enoksaparina duže.
For patients with elevated AST or ALT in the range of &gt; 5-≤ 8 x ULN or total bilirubin in the range of &gt; 3-≤ 5 x ULN that is suspected to be related to ipilimumab, the scheduled dose of ipilimumab should be withheld, and LFTs must be monitored until resolution.
U bolesnika s povišenim vrijednostima AST ili ALT u rasponu od &gt; 5-≤ 8 x GGN ili ukupnog bilirubina u rasponu od &gt; 3-≤ 5 x GGN za koje se vjeruje da su povezane s ipilimumabom, treba odgoditi primjenu planirane dozu ipilimumaba i pratiti LFT do potpunog povlačenja.
For patients with full characterisation of resistance status, 76% (84/111) were infected with an MDRH &amp; R-TB strain and 24% (27/111) with a pre-XDR-TB strain.
Za bolesnike s punom karakterizacijom statusa rezistencije, 76% (84/111) bilo je zaraženo sojem MDRH &amp; R-TB, a 24% (27/111) sa sojem pre-XDR-TB.
For patients with IA the overall rates of global response at 6 weeks were 64.3% (9/14), the global response rate was 40% (2/5) for patients 2 to &lt; 12 years and 77.8% (7/9) for patients 12 to &lt; 18 years of age.
Kod bolesnika s IA-om ukupne stope globalne reakcije nakon 6 tjedana bile su 64,3% (9/14), stopa globalne reakcije bila je 40% (2/5) za bolesnike u dobi od 2 do &lt; 12 godina i 77,8% (7/9) kod bolesnika u dobi od 12 do &lt; 18 godina.
For patients with mild hepatic impairment (total bilirubin &gt; 1 to ≤ 1.5 x ULN and aspartate aminotransferase [AST] ≤ 10 x ULN), no dose adjustments are required, regardless of indication.
U bolesnika s blagim oštećenjem jetrene funkcije (ukupni bilirubin od &gt; 1 do ≤ 1,5 x GGN i aspartat aminotransferaza [AST] ≤ 10 x GGN), prilagodbe doze nisu potrebne bez obzira na indikaciju.
For patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min) no dosage adjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥50 i &lt; 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min) no dose adjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 i &lt; 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min) no dose adjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥50 i &lt; 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min) no doseadjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 i &lt; 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (creatinine clearance &gt; 50 to ≤ 80 mL/min), no dose adjustment of alogliptin is necessary (see section 5.2).
U bolesnika s blagim oštećenjem bubrega (klirens kreatinina &gt; 50 do ≤ 80 ml/min) nije potrebna prilagodba doze alogliptina (vidjeti dio 5.2).
For patients with mild renal impairment (creatinine clearance &gt; 50 to ≤ 80 mL/min), no dose adjustment of Incresync is necessary (see section 5.2).
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina &gt; 50 do ≤ 80 ml/min) nije potrebna prilagodba doze Incresynca (vidjeti dio 5.2).
For patients with mild renal impairment (creatinine clearance ≥ 50 ml/min to &lt; 80 ml/min), dose should be adjusted and the patient stabilised using 1-monthly paliperidone palmitate injectable, then transitioned to TREVICTA.
Kod bolesnika s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 do &lt; 80 ml/min) potrebno je prilagoditi dozu, te bolesnika stabilizirati na paliperidonpalmitatu u obliku 1-mjesečne injekcije i tada prijeći na lijek TREVICTA.
For patients with mild renal impairment (creatinine clearance ≥ 50 to &lt; 80 ml/min), dose should be adjusted and the patient stabilised using 1-monthly paliperidone palmitate injectable, and then transitioned to TREVICTA.
U bolesnika s blagim oštećenjem bubrežne funkcije (klirens kreatinina ≥ 50 do &lt; 80 ml/min) potrebno je prilagoditi dozu i bolesnike stabilizirati uz uporabu paliperidonpalmitata u obliku 1-mjesečne injekcije, te nakon toga prijeći na lijek TREVICTA.
For patients with mild renal impairment (creatinine clearance ≥ 50 to &lt; 80 ml/min), the recommended initial dose is 3 mg once daily.
Kod bolesnika s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 do &lt; 80 ml/min) preporučuje se početna doza od 3 mg jedanput dnevno.
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) a dosage adjustment to one 50 mg film-coated tablet every second day is recommended (see section 5.2).
Za bolesnike s umjerenim oštećenjem bubrega (CLcr ≥30 i &lt; 50 ml/min) preporučena je prilagodba doze na jednu 50 mg filmom obloženu tabletu svaki drugi dan (vidjeti dio 5.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) a dosage adjustment to one 50 mg film-coated tablet every second day is recommended (see section 5.2).
Za bolesnike s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 i &lt; 50 ml/min) preporučena je prilagodba doze na jednu 50 mg filmom obloženu tabletu svaki drugi dan (vidjeti dio 5.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) a dosage adjustment to one 50 mg film-coated tablet every second day is recommended (see section 5.2).
Za bolesnike s umjerenim oštećenjem bubrega (klirens kreatinina ≥30 i &lt; 50 ml/min) preporučena je prilagodba doze na jednu 50 mg filmom obloženu tabletu svaki drugi dan (vidjeti dio 5.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) or severe renal impairment (CLcr &lt; 30 mL/min) an adjustment in the dose is recommended (see section 4.2).
U bolesnika s umjerenim (CLcr ≥30 i &lt; 50 ml/min) ili teškim oštećenjem bubrega (CLcr &lt; 30 ml/min) preporučuje se prilagodba doze (vidjeti dio 4.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) or severe renal impairment (CLcr &lt; 30 mL/min) being treated for the prevention of skeletal events in patients with breast cancer and metastatic bone disease an adjustment in the dose is recommended (see section 4.2).
Za bolesnike s rakom dojke i koštanim metastazama koji se liječe radi prevencije koštanih događaja te s umjerenim (CLcr ≥30 i &lt; 50 ml/min) ili teškim oštećenjem bubrega (CLcr &lt; 30 ml/min) preporučuje se prilagodba doze (vidjeti dio 4.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 ml/min) or severe renal impairment (CLcr &lt; 30 ml/min) being treated for the prevention of skeletal events in patients with breast cancer and metastatic bone disease an adjustment in the dose is recommended (see section 4.2).
Za bolesnike s rakom dojke i koštanim metastazama koji se liječe radi sprječavanja koštanih poremećaja te s umjerenim (CLcr ≥30 i &lt; 50 ml/min) ili teškim oštećenjem bubrega (CLcr &lt; 30 ml/min), se preporučuje prilagodba doze (vidjeti dio 4.2).
For patients with moderate renal impairment (CLcr ≥30 and &lt; 50 mL/min) or severe renal impairment (CLcr &lt; 30 mL/min) being treated for the prevention of skeletal events in patients with breast cancer and metastatic bone disease the following dosing recommendations should be followed:
Za bolesnike s rakom dojke i koštanim metastazama te s umjerenim oštećenjem bubrega (klirens kreatinina ≥30 i &lt; 50 ml/min) ili teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) koji se liječe radi prevencije koštanih događaja, treba slijediti sljedeće preporuke za doziranje:
For patients with moderate renal impairment (CrCl  30 to &lt; 50 mL/min), the dose of Januvia is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do &lt; 50 ml/min) doza lijeka Januvia je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to &lt; 50 mL/min), the dose of Ristaben is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do &lt; 50 ml/min) doza lijeka Ristaben je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to &lt; 50 mL/min), the dose of TESAVEL is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do &lt; 50 ml/min) doza lijeka TESAVEL je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to &lt; 50 mL/min), the dose of Xelevia is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do &lt; 50 ml/min) doza lijeka Xelevia je 50 mg jedanput na dan.
For patients with moderate to severe renal impairment (creatinine clearance  10 to &lt; 50 ml/min), the recommended initial dose of INVEGA is 1.5 mg every day, which may be increased to 3 mg once daily after clinical reassessment.
Kod bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina  10 do &lt; 50 ml/min) preporučuje se inicijalna doza od 1,5 mg svaki dan, koja se može povećati na 3 mg jednom dnevno nakon ponovne kliničke procjene.
For patients with normal baseline serum creatinine ( &lt; 1.4 mg/dl or &lt; 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l u bolesnika s normalnom početnom vrijednošću kreatinina u serumu ( &lt; 1,4 mg/dl ili &lt; 124 μmol/l)
For patients with normal baseline serum creatinine ( &lt; 1.4 mg/dl or &lt; 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l, u bolesnika s normalnom početnom vrijednošću kreatinina u serumu ( &lt; 1,4 mg/dl ili &lt; 124 μmol/l),
For patients with normal renal function (defined as CLcr &gt; 60 ml/min), zoledronic acid 4 mg/100 ml solution for infusion may be administered directly without any further preparation.
U bolesnika s normalnom funkcijom bubrega (definiranom kao CLcr &gt; 60 ml/min) zoledronatna kiselina 4 mg/100 ml otopina za infuziju može se primijeniti izravno bez ikakvog dodatnog razrjeđivanja.
For patients with normal renal function (defined as CLcr &gt; 60 ml/min), zoledronic acid 4 mg/100 ml solution for infusion may be administered directly without any further preparation.
U bolesnika s normalnom funkcijom bubrega (definiranom kao CLcr veći od 60 ml/min) zoledronatna kiselina 4 mg/100 ml otopina za infuziju može se primijeniti izravno bez ikakvog dodatnog razrjeđivanja.
For patients with normal renal function (defined as CLcr &gt; 60 ml/min), zoledronic acid 4 mg/100 ml solution for infusion may be administered directly without any further preparation.
U bolesnika s normalnom funkcijom bubrega (definiranom kao klirens kreatinina veći od 60 ml/min) zoledronatna kiselina 4 mg/100 ml otopina za infuziju može se primijeniti izravno bez ikakvog dodatnog razrjeđivanja.
For patients with renal impairment (CrCL &lt; 30 ml/min) dose reduction of clarithromycin should be considered (see section 4.4).
Smanjenje doze klaritromicina mora se razmotriti u bolesnika s oštećenom funkcijom bubrega (klirens kreatinina &lt; 30 ml/min) (vidjeti dio 4.4).
For patients with serum bilirubin levels &gt; ULN and/or ALT and AST &gt; 3.5 times the ULN concurrent with serum alkaline phosphatase levels &gt; 6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
U bolesnika s razinama serumskog bilirubina &gt; GGN i/ili ALT i AST &gt; 3,5 puta od GGN te serumskom alkalnom fosfatazom &gt; 6 puta od GGN nema preporuka za smanjenje doze te se docetaksel ne smije primijeniti osim ako to nije striktno indicirano.